3,808 Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Purchased by Merit Financial Group LLC

Merit Financial Group LLC bought a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 3,808 shares of the company’s stock, valued at approximately $520,000.

Several other large investors have also recently made changes to their positions in the business. Blue Trust Inc. grew its position in Neurocrine Biosciences by 171.9% during the 3rd quarter. Blue Trust Inc. now owns 348 shares of the company’s stock valued at $40,000 after purchasing an additional 220 shares during the last quarter. Truvestments Capital LLC bought a new position in shares of Neurocrine Biosciences in the third quarter worth approximately $63,000. True Wealth Design LLC lifted its stake in shares of Neurocrine Biosciences by 11,740.0% in the third quarter. True Wealth Design LLC now owns 592 shares of the company’s stock worth $68,000 after buying an additional 587 shares in the last quarter. Archer Investment Corp increased its position in shares of Neurocrine Biosciences by 37.0% during the third quarter. Archer Investment Corp now owns 740 shares of the company’s stock valued at $85,000 after acquiring an additional 200 shares in the last quarter. Finally, Quantbot Technologies LP purchased a new position in Neurocrine Biosciences in the 3rd quarter worth approximately $89,000. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have commented on the company. Barclays increased their target price on Neurocrine Biosciences from $160.00 to $165.00 and gave the company an “overweight” rating in a research note on Monday, December 23rd. HC Wainwright reiterated a “buy” rating and issued a $190.00 price objective on shares of Neurocrine Biosciences in a report on Monday, December 16th. Wedbush restated an “outperform” rating and set a $148.00 target price on shares of Neurocrine Biosciences in a research note on Monday, December 16th. Needham & Company LLC reiterated a “hold” rating on shares of Neurocrine Biosciences in a research note on Friday, December 20th. Finally, UBS Group increased their price objective on shares of Neurocrine Biosciences from $142.00 to $162.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. Five research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Neurocrine Biosciences has an average rating of “Moderate Buy” and an average target price of $164.81.

Insider Buying and Selling

In other Neurocrine Biosciences news, insider Ingrid Delaet sold 272 shares of the stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $138.10, for a total transaction of $37,563.20. Following the completion of the transaction, the insider now owns 2,507 shares in the company, valued at $346,216.70. This trade represents a 9.79 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Kyle Gano sold 65,000 shares of the business’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $141.50, for a total transaction of $9,197,500.00. Following the completion of the sale, the chief executive officer now owns 135,392 shares in the company, valued at approximately $19,157,968. This trade represents a 32.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 68,694 shares of company stock valued at $9,676,730. Corporate insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Price Performance

Shares of NASDAQ NBIX opened at $147.58 on Friday. Neurocrine Biosciences, Inc. has a 1 year low of $110.95 and a 1 year high of $157.98. The firm has a fifty day moving average price of $132.97 and a 200-day moving average price of $131.30. The stock has a market cap of $14.94 billion, a PE ratio of 39.57 and a beta of 0.33.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.